Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

When contemplating healthcare stocks for a long-term investment portfolio in 2026, two prominent contenders stand out: Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ). Both companies operate in the biopharmaceutical sector, yet they possess distinct characteristics that influence their appeal to investors. Bristol-Myers Squibb specializes in developing innovative medicines for serious diseases, focusing on oncology, hematology, and cardiovascular health.

The company distributes its products through wholesalers, specialty pharmacies, and direct-to-patient initiatives. In the fiscal year 2025, Bristol-Myers Squibb reported revenue of approximately $48.2 billion, a slight decline of around 0.2% compared to the previous year. Net income for the same period amounted to around $7.1 billion.

The company boasts a cash reserve of $11 billion, with $45 billion in debt outstanding, and enjoys a profit margin of 18.8% and an operating margin of 34.4% over a 12-month trailing period.

Conversely, Johnson & Johnson functions as a diversified healthcare conglomerate, comprising pharmaceutical and medical technology segments. The company provides treatments for immunology and oncology, while its medical device division serves hospitals and healthcare professionals worldwide. In fiscal year 2025, Johnson & Johnson recorded revenue of nearly $94.2 billion, marking a 6% increase from the prior year.

Net income for the full fiscal year reached nearly $26.8 billion. The company maintains a cash position of $20.7 billion, with over $49 billion in debt, resulting in a debt-to-equity ratio of 57.7%. Johnson & Johnson's profit margin stands at 16.2%, while its trailing 12-month operating margin is 25%.

Both companies navigate regulatory challenges and patent expirations, which impact their revenue streams. Bristol-Myers Squibb faces increased pricing pressures from the Inflation Reduction Act, patent expirations for key drugs, legal battles, and a $6.7 billion lawsuit related to its acquisition of Celgene. Johnson & Johnson contends with healthcare reforms affecting core drug pricing, patent challenges from biosimilar competitors, and litigation over talc-containing products.

However, Johnson & Johnson has managed to spin off its underperforming consumer healthcare division, focusing more on its pharmaceutical and medical device businesses. The company reported a 5.9% increase in sales for the third quarter of 2026, bringing in $25.4 billion, nearly double Bristol-Myers Squibb's revenue of $48.2 billion.

For income-focused investors, Bristol-Myers Squibb offers a dividend yield of 4.1%, although the company faces risks related to its drug pipeline and patent cliffs. Johnson & Johnson, on the other hand, boasts a lower dividend yield of 2.1% but has been a Dividend King for 64 consecutive years, demonstrating its reliability as a consistent dividend payer.

With its larger revenue base and focus on pharmaceutical and medical device products, Johnson & Johnson offers greater growth potential in the diversified healthcare sector. Ultimately, the choice between Bristol-Myers Squibb and Johnson & Johnson depends on an investor's priorities, whether it be income stability or growth potential.